Medical Advocates
Nucleoside/Nucleotide RTIs
  Main Page

New and Noteworthy   
General Reports   
Efficacy
Viral Dynamics
Database of ARV Drug Interactions
Resistance
Adverse Events
Drug/NRTI Interactions
Monitoring
 Pregnancy
 Pediatrics		  
HIV Main Page Main New/Newsworthy Home Page
Last Update:  August 10, 2011
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
New and Noteworthy
     
July 2011
 
 
General Reports
 

     Journal Papers, Abstracts, and Commentaries 

 
The role of nucleoside and nucleotide analogues in nodular regenerative hyperplasia
in HIV-infected patients: A case control study.
Cotte L, Bénet T, Billioud C, Miailhes P, et a
J Hepatol. 2010 Sep 19.
 Abstract

Development of a stochastic model for the efficacy of NRTIs using known mechanisms of action.
 Khalili S, Monaco JM, Armaou A.
J Theor Biol. 2010 May 24
 Abstract

Nucleoside and Nucleotide HIV Reverse Transcriptase Inhibitors: 25 Years After Zidovudine.
Cihlar T, Ray A.
Antiviral Res. 2009 Oct 31.
Abstract

A review of nucleoside reverse transcriptase inhibitor use to prevent perinatal transmission of HIV.
 Nurutdinova D, Overton ET.
Expert Opin Drug Saf. 2009 Aug 29
 Abstract

Establishment of pharmacological evaluation system for non-nucleoside reverse-transcriptase inhibitors
resistant HIV-1
 Cao YL, Li SX, Chen H, Guo Y.
 Yao Xue Xue Bao. 2009 Apr;44(4):355-61
 Abstract

Pharmacokinetic-pharmacodynamic relationship of NRTIs and its connection to viral escape:
An example based on zidovudine.
 von Kleist M, Huisinga W.
Eur J Pharm Sci. 2008 Dec 25.
Abstract
 
Impact of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) on Mitochondrial DNA and RNA in Human
Skeletal Muscle Cells.
 Saitoh A, Haas R, Naviaux R, et al
Antimicrob Agents Chemother. 2008 Jun 9.
Abstract
 

Dual Nucleoside Reverse Transcriptase Inhibitor Therapy in the Combination Antiretroviral
Therapy Era and Predictors of Discontinuation or Switch to Combination Antiretroviral Therapy.
 Selinger-Leneman H, Matheron S, Mahamat A, et al 
J Acquir Immune Defic Syndr. 2007 Oct 25;
Abstract 
 
Nucleoside Reverse-Transcriptase Inhibitor Dosing Errors in an Outpatient HIV Clinic in the
Electronic Medical Record Era.
 Willig JH, Westfall AO, Allison J, et al  
Clin Infect Dis. 2007 Sep 1;45(5):658-61.
 Abstract 
 
A WEEK-IN-REVIEW FEATURED REPORT
FULL-TEXT PDF ARTICLE
Nucleoside Analogue Reverse Transcriptase Inhibitor Options: A Re-examination of the Class.
 Hammer SM.
Top HIV Med. 2006 Oct-Nov;14(4):140-3.
 Paper
 
Nucleoside/nucleotide backbones for the treatment of HIV infection.
 Barreiro P, Jimenez-Nacher I, Garcia Bm, et al
Curr Opin Investig Drugs. 2005 Aug;6(8):812-22.
 
Antiretroviral Treatment Simplification With 3 NRTIs or 2 NRTIs Plus Nevirapine in HIV-1-Infected
Patients Treated With Successful First-Line HAART.
 Bonjoch A, Paredes R, Galvez J, et al 
J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):313-316.
Abstract 
 
The Pharmacology of Antiretroviral Nucleoside and Nucleotide Reverse Transcriptase
Inhibitors: Implications for Once-Daily Dosing.
 Back DJ, Burger DM, Flexner CW, Gerber JG.
Acquir Immune Defic Syndr. 2005 Aug 1;39 Suppl 1:S1-S23.
Abstract 
 
New Nucleoside/Nucleotide Backbone Options: A Review of Recent Studies.
 Ruane PJ, DeJesus E.  
J Acquir Immune Defic Syndr. 2004 Sep 1;37:S21-S29
 Abstract 
 
Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors.
 Piliero PJ.
J Acquir Immune Defic Syndr. 2004 Sep 1;37 Suppl 1:S2-S12
 Abstract 
 
The role of nucleoside and nucleotide reverse transcriptase inhibitor backbones in
antiretroviral therapy.
 Young B.  
J Acquir Immune Defic Syndr. 2004 Sep 1;37 Suppl 1:S13-20
 Abstract 
 
The ideal nucleoside/nucleotide backbone.
Gallant JE   
J Acquir Immune Defic Syndr. 2004 Sep 1;37 Suppl 1:S44-51.
 Abstract 
 
Nucleoside analogue use before and during highly active antiretroviral therapy and virus load
rebound.
Collaboration of HIV Cohorts. 
J Infect Dis. 2004 Aug 15;190(4):675-87.
 Abstract 

Trends in the Design of Nucleoside Analogues as Anti-HIV Drugs.
 el Kouni MH.
 Curr Pharm Des 2002;8(8):581-9
 Abstract 
 
        Conference Reports, Abstracts, and Posters

  The effects of nucleos(t)ide reverse transcriptase inhibitors on telomerase reverse transcriptase
activity and telomere length in peripheral blood mononuclear cells of HIV-1-infected individuals
 E. Leeansyah, P. Cameron, A. Solomon, et al
(6th IAS Conference)
 Abstract

Rate of Virological Failure and Resistance Mutations in HIV+ Patients Treated with Distinct
Triple Nucleos(t)ide Combinations
L. MARTIN-CARBONERO, P. GIL, et al 
(45 ICAAC(
 Abstract
Efficacy
 

     Journal Papers, Abstracts, and Commentaries 

 
Immunovirological Response to Triple Nucleotide Reverse-Transcriptase Inhibitors and
Ritonavir-Boosted Protease Inhibitors in Treatment-Naive HIV-2-Infected Patients: The ACHIEV2E
Collaboration Study Group.
Benard A, van Sighem A, Taieb A,  et al
Clin Infect Dis. 2011 May;52(10):1257-1266
 Abstract 

FULL-TEXT ARTICLE
Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside
reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus
non-NRTI or only NRTI containing NRTI plus non-NRTI or only NRTI.
Torti C, d'Arminio-Monforte A, Pozniak AL,  et al
BMC Infect Dis. 2011 Jan 25;11(1):23.
 Paper

Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy
for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals.
 Imaz A, Llibre JM, Mora M,  et al
J Antimicrob Chemother. 2010 Dec 14.
Abstract 

Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients:
systematic review and meta-analysis.
Chowers M, Gottesman BS, Leibovici L, et al
Eur J Clin Microbiol Infect Dis. 2010 May 7.
 Abstract

Quantifying the treatment efficacy of reverse transcriptase inhibitors: new analyses of clinical
data based on within-host modeling.
 Breban R, Napravnik S, Kahn J, Blower S.
BMC Public Health. 2009 Nov 18;9 Suppl 1:S11.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line
boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression
analysis of 12 clinical trials in 5168 patients.
Hill A, Sawyer W. 
HIV Med. 2009 Oct;10(9):527-35.
 Abstract

Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with
regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.
 Duvivier C, Ghosn J, Assoumou L, Soulié C, et al
J Antimicrob Chemother. 2008 Jul 18.
Abstract
 
A comparison of three highly active antiretroviral treatment strategies consisting of
non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the
presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058
FIRST Study): a long-term randomised trial.
 MacArthur RD, Novak RM, Peng G, et al
Lancet. 2006 Dec 16;368(9553):2125-35.
 Abstract
 
Nucleoside  Reverse Transcriptase  Inhibitors Prevent HIV Protease  Inhibitor Induced 
Atherosclerosisby  Ubiquitination and Degradation of Protein Kinase E C.
 Bradshaw EL, Li XA, Guerin T, et al
 Am J Physiol Cell Physiol. 2006 Jul 5;
Abstract

Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase
inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort
of French HIV-infected patients.
 Cuzin L, Pugliese P, Bugnon F, et al 
HIV Med. 2005 Nov;6(6):388-95.
 Abstract
 
Three-Year Durability of Dual-Nucleoside Versus Triple-Nucleoside Therapy in a Thai Population
With HIV Infection.
 Behalf of the HIV-NAT 002 and HIV-NAT 003 Study Team.
J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):693-701}
 Abstract
 
Immune reconstitution is comparable in antiretroviral-naive subjects after 1 year of successful
therapy with a nucleoside reverse-transcriptase inhibitor- or protease inhibitor-containing
antiretroviralregimen.
 Landay AL, Spritzler J, Kessler H, et al 
J Infect Dis. 2003 Nov 15;188(10):1444-54.
 Abstract 
 
Safety and efficacy of switching to alternative nucleoside analogues following symptomatic h
yperlactatemia and lactic acidosis.
 Lonergan JT, Barber RE, Mathews WC.   
AIDS. 2003 Nov 21;17(17):2495-9.
Abstract 

Differential susceptibility of retroviruses to nucleoside analogues.
 Rosenblum LL, Patton G, Grigg AR et al.
 Antivir Chem Chemother 2001 Mar;12(2):91-7
 Abstract 

Therapeutic effects of nucleoside analogues on psychomotor slowing in HIV infection.
Arendt G, von Giesen HJ, Hefter H, Theisen A
AIDS 2001 Mar 9;15(4):493-500
 Abstract
 
        Conference Reports, Abstracts, and Posters

  Long-term glucose tolerance in highly experienced patients receiving NRTI-sparing regimens
 A. Bigoloni, V. Spagnuolo, L. Galli, et al.
(6th IAS Conference)
 Abstract
Viral Dynamics Data
 

          Journal Papers, Abstracts, and Commentaries
 
 
Time to Virological Failure of 3 Classes of Antiretrovirals after Initiation of Highly Active Antiretroviral Therapy:
Results from the EuroSIDA Study Group.
 Mocroft A, Ledergerber B, Viard JP, et  al. 
J Infect Dis. 2004 Dec 1;190(11):1947-1956.
 Abstract

FULL-TEXT PDF ARTICLE   
Comparative CD4 T-cell responses of reverse transcriptase inhibitor therapy with or without
nelfinavir matched for viral exposure.
 Kravcik S, Magill A, Sanghvi B, et al
 HIV Clin Trials 2001 Mar-Apr;2(2):160-70
 Paper
Resistance Data
 

     Journal Papers, Abstracts, and Commentaries

 
Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral
Treatment Failure: A Systematic Review and Pooled Analysis.
 Li JZ, Paredes R, Ribaudo HJ, et al
JAMA. 2011 Apr 6;305(13):1327-35.
 Abstract

A Novel Molecular Mechanism of Dual Resistance to NRTIs and NNRTIs.
 Nikolenko GN, Delviks-Frankenberry KA, Pathak VK.
 J Virol. 2010 Mar 10.
 Abstract

Nucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human
immunodeficiency viruses 1 and 2.
 Ntemgwa ML, Toni TD, Brenner BG,et al 
Antimicrob Agents Chemother. 2008 Dec 8.
Abstract
 
Impact of unreported HIV-1 reverse transcriptase mutations on phenotypic resistance to nucleoside and
non-nucleoside inhibitors.
 Saracino A, Monno L, Scudeller L, et al 
J Med Virol. 2005 Nov 18;78(1):9-17
Abstract

Prevalence of complete resistance to at least two classes of antiretroviral drugs in treated
HIV-1-infected patients: A French nationwide study.
 Masquelier B, Costagliola D, Schmuck A .
 J Med Virol. 2005 Aug;76(4):441-6.
Abstract
Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of a
ntiretroviral resistance.
Gallant JE, Gerondelis PZ, Wainberg MA, et al
Antivir Ther. 2003 Dec;8(6):489-506
 Abstract
 
Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency
virus type 1 clinical isolates.
 Whitcomb JM, Parkin NT, Chappey C, et al
 J Infect Dis. 2003 Oct 1;188(7):992-1000.
 Abstract

FULL-TEXT ARTICLE             
Establishment of new transmissible and drug-sensitive human immunodeficiency
virus type 1 wild types due to transmission of nucleoside analogue-resistant virus.
 de Ronde A, van Dooren M, van Der Hoek
Virol 2001 Jan;75(2):595-602 
Paper
 

  
  Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse
transcriptase inhibitor therapy.
 van der Ende ME, Guillon C, Boers , et al 
J Acquir Immune Defic Syndr 2000 Sep 1;25(1):11-8      
Abstract
 		  
  FULL-TEXT ARTICLE   
Prevalence and characteristics of multinucleoside-resistant human immunodeficiency
virus type 1 among European patients receiving combinations of nucleoside analogues.
 Van Vaerenbergh K, Van Laethem K, Albert J, et al.
 Antimicrob Agents Chemother 2000 Aug;44(8):2109-17
 Paper
 		  
         Conference Reports, Abstracts, and Posters

 
Mutations of multiresistance associated to the use of nucleoside/nucleotide reverse transcriptase inhibitors
in Western México
 B.M. Torres Mendoza, M. Escoto-Degadillo, B.M. Vázquez-Torres,  et al  
(XVII International AIDS Conference)
 Abstract

Unexplained Protease Inhibitor (PI) Resistance in Clinical Isolates Lacking Known Primary
PI Mutations
 N T. PARKIN, C. CHAPPEY, E. LAM, C. J. PETROPOULOS; et al 
(45 ICAAC)
 Abstract
Drug/NRTI Interactions
 

Ribavirin

          Journal Papers, Abstracts, and Commentaries
 
  Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse
transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus
coinfection: results of a randomized clinical study.
 Rodriguez-Torres M, Torriani FJ, Soriano V, et al
 Antimicrob Agents Chemother. 2005 Oct;49(10):3997-4008.
 Abstract
Monitoring
 
          Journal Papers, Abstracts, and Commentaries
 
  FULL-TEXT ARTICLE
 Measuring Enzymatic HIV-1 Susceptibility to Two Reverse Transcriptase Inhibitors as a Rapid and Simple
Approach to HIV-1 Drug-Resistance Testing.
 Hoffmann D, Garcia AD, Harrigan PR, et al
PLoS One. 2011;6(7):e22019.
Paper

Development and validation of a liquid chromatographic/tandem mass spectrometric assay for the
quantitation of nucleoside HIV reverse transcriptase inhibitors in biological matrices.
Compain S, Schlemmer D, Levi M,et al
 Mass Spectrom. 2005 Jan 11;40(1):9-18
 Abstract
Pregnancy Data
 

          Journal Papers, Abstracts, and Commentaries

 
Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse
transcriptase inhibitors in human immunodeficiency virus-infected pregnant women.
Chappuy H, Treluyer JM, Jullien V, et al 
Antimicrob Agents Chemother. 2004 Nov;48(11):4332-6.
 Abstract  

Antiretroviral agents and pregnancy: mitochondrial dysfunction and nucleoside analogs
 Loubeyre-Unique C, Gautier A, Vauzelle-Gardier C, et al,       
Therapie 2001 May-Jun;56(3):261-6
Abstract     

Risk of early febrile seizure with perinatal exposure to nucleoside analogues.
 Landreau-Mascaro A, Barret B,  Mayaux MJ, et al.
Lancet 2002 Feb 16;359(9306):583-4  
 Abstract    
Pediatric Data
 

          Journal Papers, Abstracts, and Commentaries

 
Pattern and predictors of immunologic recovery in human immunodeficiency virus-infected children
receiving non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy.
Puthanakit T, Kerr S, Ananworanich J, et al
Pediatr Infect Dis J. 2009 Jun;28(6):488-92.
 Abstract

Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic
response to combination therapy in children (PACTG 338).
 Fiscus SA, Kovacs A, Petch LA, et al  
AIDS Res Ther. 2007 Feb 6;4(1):2
Abstract

Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for
pretreated children infected with human immunodeficiency virus type 1.
 Krogstad P, Lee S, Johnson G, Stanley K, et al.
Clin Infect Dis 2002 Apr 1;34(7):991-1001
 Abstract

 

HIV Main Page Main New/Newsworthy Home Page

Nucleoside/Nucleotide Reverse Transcriptase Inhibitors